Recent Developments, Liquidity and Management's Plans (Details Narrative) |
1 Months Ended | 12 Months Ended | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Feb. 25, 2021
USD ($)
|
Jan. 21, 2021
USD ($)
|
Nov. 17, 2020
USD ($)
$ / shares
shares
|
Nov. 12, 2020
Integer
|
Nov. 11, 2020
USD ($)
$ / shares
shares
|
Oct. 31, 2020
USD ($)
$ / shares
shares
|
Oct. 13, 2020
USD ($)
|
Aug. 13, 2020
USD ($)
|
May 18, 2020
USD ($)
|
May 14, 2020 |
Apr. 20, 2020
USD ($)
|
Apr. 10, 2020
USD ($)
|
Apr. 08, 2020
USD ($)
$ / shares
shares
|
Mar. 24, 2020
USD ($)
shares
|
Mar. 23, 2020
USD ($)
|
Feb. 23, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
|
Dec. 31, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
|
| Research and development expenses | $ 7,963,678 | ||||||||||||||||||
| Liabilities | 2,263,295 | 1,529,765 | |||||||||||||||||
| Trade and Other Payables | 2,203,902 | 891,883 | |||||||||||||||||
| Cash | 18,617,955 | 517,444 | |||||||||||||||||
| Marketable securities | 16,718,452 | ||||||||||||||||||
| Net loss | (17,580,609) | (3,888,249) | |||||||||||||||||
| Working capital | 34,579,466 | ||||||||||||||||||
| Net cash used in operating activities | (11,924,941) | (3,074,283) | |||||||||||||||||
| Net loss from continuing operations | (12,152,214) | (3,381,295) | |||||||||||||||||
| Net loss from discontinuing operations | (5,428,395) | (506,954) | |||||||||||||||||
| Stockholders equity | 34,579,466 | 9,355,170 | $ 5,833,753 | ||||||||||||||||
| Accumulated deficit | (137,163,739) | (119,583,130) | |||||||||||||||||
| Trading days | Integer | 10 | ||||||||||||||||||
| Deposits and Other Receivables | 1,200,009 | ||||||||||||||||||
| Proceeds from common stock | 29,184,244 | 2,147,778 | |||||||||||||||||
| Net proceeds from issuance of pre-funded warrants for the purchase of common stock | 1,743,503 | 4,817,857 | |||||||||||||||||
| Private Placement [Member] | |||||||||||||||||||
| Share price | $ / shares | $ 1.85 | ||||||||||||||||||
| Stock issued during the period | shares | 8,725,393 | ||||||||||||||||||
| Proceeds from common stock | $ 16,362,786 | ||||||||||||||||||
| Warrants exercise price | $ / shares | $ 1.85 | ||||||||||||||||||
| Net proceeds from issuance of pre-funded warrants for the purchase of common stock | $ 932,432 | ||||||||||||||||||
| Holder [Member] | Private Placement [Member] | |||||||||||||||||||
| Warrants description | A holder (together with its affiliates) may not exercise any portion of the Investor Warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder prior to the date of issuance, 9.99%) of the outstanding Akers common stock immediately after exercise; provided, however that upon notice to Akers, the holder may increase or decrease the beneficial ownership limitation, provided that in no event shall the beneficial ownership limitation exceed 9.99% | ||||||||||||||||||
| Former Members [Member] | Private Placement [Member] | |||||||||||||||||||
| Proceeds from issuance of private placement | $ 1,204,525 | ||||||||||||||||||
| Minimum [Member] | |||||||||||||||||||
| Share price | $ / shares | $ 5.00 | ||||||||||||||||||
| Premas Biotech PVT Ltd [Member] | |||||||||||||||||||
| Trade and Other Payables | 1,510,290 | ||||||||||||||||||
| Phase I Clinical Trial [Member] | |||||||||||||||||||
| Contingent payments upon achievement of certain milestones | 250,000 | ||||||||||||||||||
| Phase II Clinical Trial [Member] | |||||||||||||||||||
| Contingent payments upon achievement of certain milestones | 500,000 | ||||||||||||||||||
| Phase III Clinical Trial [Member] | |||||||||||||||||||
| Contingent payments upon achievement of certain milestones | 5,000,000 | ||||||||||||||||||
| COVID-19 Vaccine [Member] | |||||||||||||||||||
| Contingent payments upon achievement of certain milestones | 15,000,000 | ||||||||||||||||||
| Royalty payments, description | The Company shall also make quarterly royalty payments to Sellers equal to 5% of the net sales of a COVID-19 vaccine or combination product by the Company (the "COVID-19 Vaccine") for a period of five (5) years following the first commercial sale of the COVID-19 Vaccine; provided, that such payment shall be reduced to 3% for any net sales of the COVID-19 Vaccine above $500 million. | ||||||||||||||||||
| Pre-Funded Warrants [Member] | Private Placement [Member] | |||||||||||||||||||
| Stock issued during the period | shares | 9,765,933 | ||||||||||||||||||
| Warrants exercise price | $ / shares | $ 0.01 | ||||||||||||||||||
| Investor Warrants [Member] | Private Placement [Member] | |||||||||||||||||||
| Stock issued during the period | shares | 9,765,933 | ||||||||||||||||||
| Warrants exercise price | $ / shares | $ 2.06 | $ 2.06 | |||||||||||||||||
| Common Stock [Member] | |||||||||||||||||||
| Net loss | |||||||||||||||||||
| Stockholders equity | 171,598,681 | 128,920,414 | $ 121,554,547 | ||||||||||||||||
| Stock issued during the period | shares | 8,725,393 | ||||||||||||||||||
| Proceeds from common stock | $ 18,066,976 | ||||||||||||||||||
| Shares issued price per share | $ / shares | $ 1.85 | ||||||||||||||||||
| Series D Convertible Preferred Stock [Member] | |||||||||||||||||||
| Stockholders equity | |||||||||||||||||||
| Katalyst Securities LLC [Member] | |||||||||||||||||||
| Warrants exercise price | $ / shares | $ 1.85 | ||||||||||||||||||
| Equal fee percent | 6.50% | ||||||||||||||||||
| Proceeds from issuance of private placement | $ 25,000 | ||||||||||||||||||
| Katalyst Securities LLC [Member] | Maximum [Member] | |||||||||||||||||||
| Purchase of warrants | shares | 390,368 | ||||||||||||||||||
| Membership Interest Purchase Agreement [Member] | |||||||||||||||||||
| Research and development expenses | 5,867,046 | ||||||||||||||||||
| Payment to sellers | $ 1,204,525 | $ 1,000,000 | |||||||||||||||||
| Proceeds from initial equity offering | $ 8,000,000 | ||||||||||||||||||
| Percentage of payment to sellers on equity offering | 10.00% | ||||||||||||||||||
| Additional cash consideration | $ 10,000,000 | ||||||||||||||||||
| Achievement of milestone, description | Upon the achievement of certain milestones, including the completion of a Phase 2 study for a COVID-19 vaccine that meets its primary endpoints, Sellers will be entitled to receive an additional 750,000 shares of our common stock or, in the event we are unable to obtain stockholder approval for the issuance of such shares, 750,000 shares of non-voting preferred stock that are valued following the achievement of such milestones and shall bear a 10% annual dividend (the "Milestone Shares"). | ||||||||||||||||||
| Contingent payments upon achievement of certain milestones | $ 250,000 | ||||||||||||||||||
| Liabilities | 602,172 | ||||||||||||||||||
| Royalty payments to sellers, percentage | 0.125 | ||||||||||||||||||
| Membership Interest Purchase Agreement [Member] | Cystron and Premas [Member] | |||||||||||||||||||
| Purchase of initial cash component | $ 908,117 | ||||||||||||||||||
| Membership Interest Purchase Agreement [Member] | Cystron [Member] | |||||||||||||||||||
| Ownership percentage | 100.00% | ||||||||||||||||||
| Membership Interest Purchase Agreement [Member] | Premas Biotech PVT Ltd [Member] | |||||||||||||||||||
| Achievement of milestone, description | The Company and Premas agreed that the fourth milestone under the License Agreement had been satisfied. Due to the achievement of this milestone on July 7, 2020, Premas was paid $1,000,000 on August 4, 2020. Accordingly, for the year ended December 31, 2020, Research and Development Expenses of $2,000,000 were recorded in the Consolidated Statements of Comprehensive Loss. | ||||||||||||||||||
| Membership Interest Purchase Agreement [Member] | May Payment [Member] | |||||||||||||||||||
| Payment to sellers upon consummation direct equity offering | $ 892,500 | ||||||||||||||||||
| Membership Interest Purchase Agreement [Member] | August Payment [Member] | |||||||||||||||||||
| Payment to sellers upon consummation direct equity offering | $ 684,790 | ||||||||||||||||||
| Membership Interest Purchase Agreement [Member] | Cystron Biotech, LLC [Member] | |||||||||||||||||||
| Agreement description | As consideration for the Membership Interests (as defined in the MIPA), the Company delivered to the members of Cystron (the "Sellers"): (1) that number of newly issued shares of its common stock equal to 19.9% of the issued and outstanding shares of its common stock and pre-funded warrants as of the date of the MIPA, but, to the extent that the issuance of its common stock would have resulted in any Seller owning in excess of 4.9% of the Company's outstanding common stock, then, at such Seller's election, such Seller received "common stock equivalent" preferred shares with a customary 4.9% blocker (with such common stock and preferred stock collectively referred to as "Common Stock Consideration"), and (2) $1,000,000 in cash. On March 24, 2020 the Company paid $1,000,000 to the Sellers and delivered 411,403 shares of common stock and 211,353 shares of Series D Convertible Preferred Stock with a customary 4.9% blocker, with an aggregate fair market value of $1,233,057, and recorded $2,233,057 ("March Transaction"). | ||||||||||||||||||
| Proceeds from collaborators | $ 1,000,000 | ||||||||||||||||||
| Payment to the sellers | $ 1,000,000 | ||||||||||||||||||
| Membership Interest Purchase Agreement [Member] | Cystron Biotech, LLC [Member] | Premas Biotech PVT Ltd [Member] | |||||||||||||||||||
| Achievement of milestone, description | Upon the achievement of certain developmental milestones by Cystron, Cystron shall pay to Premas a total of up to $2,000,000. On April 16, 2020, the Company paid Premas $500,000 for the achievement of the first two development milestones. On May 18, 2020, the Company paid Premas $500,000 for the achievement of the third development milestone. | ||||||||||||||||||
| Membership Interest Purchase Agreement [Member] | Cystron Biotech, LLC [Member] | Common Stock [Member] | |||||||||||||||||||
| Number of shares delivered | shares | 411,403 | ||||||||||||||||||
| Fair market value shares delivered | $ 1,233,057 | ||||||||||||||||||
| Research and development expenses | $ 2,233,057 | ||||||||||||||||||
| Membership Interest Purchase Agreement [Member] | Cystron Biotech, LLC [Member] | Series D Convertible Preferred Stock [Member] | |||||||||||||||||||
| Number of shares delivered | shares | 211,353 | ||||||||||||||||||
| Percentage of blocker | 4.90% | ||||||||||||||||||
| Fair market value shares delivered | $ 1,233,057 | ||||||||||||||||||
| Research and development expenses | $ 2,233,057 | ||||||||||||||||||
| License Agreement [Member] | |||||||||||||||||||
| Research and development expenses | 2,000,000 | ||||||||||||||||||
| Cystron Medical Panel [Member] | |||||||||||||||||||
| Research and development expenses | 31,573 | ||||||||||||||||||
| Achievement of milestone, description | The Cystron Medical Panel and appointed its first member to the panel. Each member shall be compensated with an initial grant of the Company's common stock with an aggregate fair market value of $25,000 and a monthly cash stipend in the initial amount of $2,500 | ||||||||||||||||||
| Fair market value common stock | $ 25,000 | ||||||||||||||||||
| Monthly cash stipend in initial amount | $ 2,500 | ||||||||||||||||||
| Merger Agreement [Member] | Minimum [Member] | Private Placement [Member] | |||||||||||||||||||
| Cash | $ 25,000,000 | ||||||||||||||||||
| Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | |||||||||||||||||||
| Ownership percentage | 80.00% | ||||||||||||||||||
| Stock issued during the period | shares | 300,000 | ||||||||||||||||||
| Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Secured Promissory Note [Member] | |||||||||||||||||||
| Debt instrument, maturity date | Apr. 15, 2022 | ||||||||||||||||||
| Deposits and Other Receivables | $ 1,200,000 | ||||||||||||||||||
| Proceeds from issuance of debt | $ 1,200,000 | $ 600,000 | |||||||||||||||||
| Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Extended Maturity [Member] | |||||||||||||||||||
| Debt instrument, maturity date description | The Merger Agreement contains certain termination rights for both the Company and MYMD, including, among other things, (a) Akers may, upon written notice, extend the originally scheduled End Date (defined in the Merger Agreement as April 15, 2021) to May 15, 2021 (the "Extended Date") so long as (i) Akers and Merger Sub are not then in material breach of any provision of the Merger Agreement and (ii) within three calendar days of the written request by MYMD, Akers makes an additional loan to MYMD of up to $600,000, which will have the same terms and conditions of the Note (as defined below and such additional note "Second Note") and (b) Akers may, upon written notice, extend the Extended Date to June 30, 2021, so long as (i) Akers and Merger Sub are not then in material breach of any provision of the Merger Agreement, (ii) on the effective date of such extension, the loan amount evidenced by the Note and the Second Note may, at the sole option of MYMD upon written notice to Akers, be converted into shares of MYMD common stock at a conversion price of $2.00 per share, subject to certain adjustments and (iii) Akers will, at MYMD's request, either (at the option of MYMD); (A) subscribe for 300,000 shares of MYMD common stock at a subscription price of $2.00 per share, subject to certain adjustments as set forth in the Merger Agreement, or (B) makes an additional loan to MYMD of up to $600,000, which will have the same terms and conditions of the Note (the "Third Note," and all amounts outstanding under the Note, the Second Note and the Third Note, the "Loan Amount"). In addition, if Akers terminates the Merger Agreement under certain circumstances specified therein, the Loan Amount, if any, at the sole discretion of MYMD, will be convertible into shares of common stock of MYMD at a conversion price of $2.00 per share upon delivery of written notice by MYMD to Akers within 30 calendar days after the effective date of termination of the Merger Agreement. | ||||||||||||||||||
| Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | |||||||||||||||||||
| Loans payable | $ 3,000,000 | ||||||||||||||||||
| Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | Second Note [Member] | |||||||||||||||||||
| Loans payable | 600,000 | ||||||||||||||||||
| Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | Third Note [Member] | |||||||||||||||||||
| Loans payable | $ 600,000 | ||||||||||||||||||
| Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | Secured Promissory Note [Member] | |||||||||||||||||||
| Conversion price, per share | $ / shares | $ 2.00 | ||||||||||||||||||
| Loans payable | $ 3,000,000 | ||||||||||||||||||
| Debt instrument, interest rate | 5.00% | ||||||||||||||||||
| Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Minimum [Member] | |||||||||||||||||||
| Share price | $ / shares | $ 5.00 | ||||||||||||||||||
| Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Post-Closing Shares [Member] | |||||||||||||||||||
| Ownership percentage | 20.00% | ||||||||||||||||||
| Securities Purchase Agreement [Member] | Accredited Investors [Member] | |||||||||||||||||||
| Share price | $ / shares | $ 1.85 | $ 6.00 | |||||||||||||||||
| Stock issued during the period | shares | 9,765,933 | 766,667 | |||||||||||||||||
| Proceeds from common stock | $ 18,100,000 | $ 4,086,207 | |||||||||||||||||
| Prepaid Equity Forward Contracts [Member] | |||||||||||||||||||
| Stock issued during the period | shares | 1,040,540 | ||||||||||||||||||
| Proceeds from common stock | $ 16,362,786 | ||||||||||||||||||